Practical guides on medical device registration and international expansion.
Each change checked against the authority's own instrument. Every dated change is also on the regulatory change tracker.
Registration isn't payment. How each market pays for a device, who decides, who is paid, and six ways a reimbursement figure gets misread.
Eight countries, including France, Switzerland and Australia, have a military route for devices that are not yet approved. In every one, the military holds it, not the manufacturer.
RAPID is still a proposal, TCET is closed to new devices, and the NTAP shortcut is gone. Who RAPID is for, and what to do now.
The regulatory line in a device deck is public record. Approvals and dates, the local license holder, the predicate chain, class by market, the order of markets, and who is already registered.
Investors read the regulatory plan as the revenue plan. Six things it should show, from the route in each market to how far the money goes.
From 1 November 2026, Australian clinical decision support software stays off the ARTG only if it passes five tests, including showing its logic and not making the decision itself. What changed, which software now needs ARTG…
November deadlines in the EU, China and Australia; new rules for AI and software devices in Australia, Indonesia and the EU; easier entry in India, Korea, Vietnam and Taiwan; the EU's first device HTA picks; higher US fees.…
Japan has a draft for generative-AI devices, Great Britain has 44 government commitments, and the EU moved the AI Act to 2028 for devices. What differs, what carries across, and what an AI device company should file first.…
Thailand now recognizes Malaysian device approvals in law, which completes a loop of reliance routes between Malaysia, Singapore and Thailand. With Malaysia's expiring classification letters, Indonesia's local validation for…
What changed for medical device makers in Canada, Mexico, Colombia, Chile and Argentina from August to October 2026, with a dated calendar of the deadlines that follow. Most of the new work falls on your local importer or…
Singapore's partnerships, Kenya's GMP reliance guideline, India's IVD documents, Mexico's ANVISA pathway and the UK's 14-day Phase 1 review were all read as device news. What each instrument actually says, the device route…
The EU selected two transcatheter mitral valves for its first device joint clinical assessments. Which devices can be selected, the timeline after CE marking, what you must submit, the one lever a startup has, and where…
What CDSCO published on in-vitro diagnostics in 2026, which documents are drafts, when comments close, and why the August EU waiver does not reach a new IVD. Checked against the Medical Devices Rules and each document.
From October 2026 Taiwan files and records device clinical trials on one platform: what changed in the application instructions, what a running trial must now do, and why a startup should look again at Taiwan for an early study.
Reliance is not one mechanism. In 8 markets a foreign approval is required before you can file at all; in 9 it just makes the filing cheaper. We verified 28 markets — nine of the ones we checked were wrong.
1,639 UK Responsible Persons represent 7,935 foreign manufacturers. Who they are, how concentrated the market really is, and what to ask before you appoint one.
Who can hold your registration, what class you land in, who is already there, what your approvals are worth, and how anyone actually gets paid.
Listing the multinationals captures 87% of the field in Hong Kong and 10% in China. A method that works either way.
Most assessments answer questions nobody asked. What a useful one contains — and how to tell before you commission it.
Your distributor holds your market access. The candidate list, and what each already distributes, is in the registration record.
Brazil is the region, mostly. Costa Rica's register is a manufacturing artefact, not demand. An honest read.
Regulatory due diligence before the contract. Distribution agreements in this region are hard to exit — do this first.
The specific failure modes, and when the manual approach stops working. Honest take.
The standard advice is "start with Singapore." That's not always wrong — but it's not always right either. A decision framework.
Most companies come to us with one of these four questions. Each one is a conversation, not a form.
Talk to us about your expansion plans, and see yourself in our solution.